Peripheral arterial disease (PAD) and chronic kidney disease (CKD) are associated with increased mortality rates. We assessed long-term outcomes of patients with PAD and CKD. Patients with PAD undergoing invasive angiography and/or endovascular revascularization between 2005 and 2010 were retrospectively classified into 5 CKD stages. A follow-up was performed and 572 patients were included, 116 patients (20%) had normal renal function, 245 were in CKD stage 2 (43%), 156 in CKD stage 3 (27%), and 55 in CKD stages 4 + 5 (10%). Diabetes mellitus, hypertension, and anemia were more frequent in higher CKD stages (P < .03). During follow-up (mean 1135 days; 95% confidence interval 1159-1259), cumulative mortality was 21% and increased with advanced CKD stages (9%, 16%, 29%, and 47%, respectively, P < .001). In multivariate Cox regression models, higher CKD stages were significantly associated with poor survival. Medication adherence for secondary prevention was significantly lower than recommended but irrespective of CKD stages. Kidney function is an independent predictor of worse long-term survival in patients with PAD. While standard medications were used less often than recommended, no differences between CKD stages were noted.
SelvinEErlingerTP. Prevalence of and risk factors for peripheral arterial disease in the United States: results from the National Health and Nutrition Examination Survey, 1999-2000. Circulation. 2004;110(6):738–743.
2.
GolombBADangTTCriquiMH. Peripheral arterial disease: morbidity and mortality implications. Circulation. 2006;114(7):688–699.
3.
FowkesFGRudanDRudanI. Comparison of global estimates of prevalence and risk factors for peripheral artery disease in 2000 and 2010: a systematic review and analysis. Lancet. 2013;382(9901):1329–1340.
4.
MalyarNFürstenbergTWellmannJ. Recent trends in morbidity and in-hospital outcomes of in-patients with peripheral arterial disease: a nationwide population-based analysis. Eur Heart J. 2013;34(34):2706–2714.
5.
ZhangQLRothenbacherD. Prevalence of chronic kidney disease in population-based studies: systematic review. BMC Public Health. 2008;8:117.
6.
MannJFGersteinHCPogueJBoschJYusufS. Renal insufficiency as a predictor of cardiovascular outcomes and the impact of ramipril: the HOPE randomized trial. Ann Intern Med. 2001;134(8):629–636.
7.
Di AngelantonioEChowdhuryRSarwarNAspelundTDaneshJGudnasonV. Chronic kidney disease and risk of major cardiovascular disease and non-vascular mortality: prospective population based cohort study. BMJ. 2010;341: c4986.
8.
GoASChertowGMFanDMcCullochCEHsuCY. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med. 2004;351(13):1296–1305.
9.
CriquiMHLangerRDFronekA. Mortality over a period of 10 years in patients with peripheral arterial disease. N Engl J Med. 1992;326(6):381–386.
10.
O’HareAMBertenthalDShlipakMGSenSChrenMM. Impact of renal insufficiency on mortality in advanced lower extremity peripheral arterial disease. J Am Soc Nephrol. 2005;16(2):514–519.
11.
ReineckeHTreyTMatzkiesF. Grade of chronic renal failure, and acute and long-term outcome after percutaneous coronary interventions. Kidney Int. 2003;63(2):696–701.
12.
WattanakitKFolsomARSelvinECoreshJHirschATWeatherleyBD. Kidney function and risk of peripheral arterial disease: results from the Atherosclerosis Risk in Communities (ARIC) Study. J Am Soc Nephrol. 2007;18(2):629–636.
13.
LiewYPBartholomewJRDemirjianSMichaelsJSchreiberMJJr. Combined effect of chronic kidney disease and peripheral arterial disease on all-cause mortality in a high-risk population. Clin J Am Soc Nephrol. 2008;3(4):1084–1089.
14.
LuoYLiXLiJ. Peripheral arterial disease, chronic kidney disease, and mortality: The Chinese Ankle Brachial Index Cohort Study. Vasc Med. 2010;15(2):107–112.
15.
LacroixPAboyansVDesormaisI. Chronic kidney disease and the short-term risk of mortality and amputation in patients hospitalized for peripheral artery disease. J Vasc Surg. 2013;58(4):966–971.
16.
EzekowitzJMcAlisterFAHumphriesKH. The association among renal insufficiency, pharmacotherapy, and outcomes in 6,427 patients with heart failure and coronary artery disease. J Am Coll Cardiol. 2004;44(8):1587–1592.
17.
AnavekarNSMcMurrayJJVelazquezEJ. Relation between renal dysfunction and cardiovascular outcomes after myocardial infarction. N Engl J Med. 2004;351(13):1285–1295.
18.
YanATYanRTTanM. Optimal medical therapy at discharge in patients with acute coronary syndromes: temporal changes, characteristics, and 1-year outcome. Am Heart J. 2007;154(6):1108–1115.
19.
FoxCSMuntnerPChenAY. Use of evidence-based therapies in short-term outcomes of ST-segment elevation myocardial infarction and non-ST-segment elevation myocardial infarction in patients with chronic kidney disease: a report from the National Cardiovascular Data Acute Coronary Treatment and Intervention Outcomes Network registry. Circulation. 2010;121(3):357–365.
20.
CardinalHBogatyPMadoreFBoyerLJosephLBrophyJM. Therapeutic management in patients with renal failure who experience an acute coronary syndrome. Clin J Am Soc Nephrol. 2010;5(1):87–94.
21.
BlassKGThibertRJLamLK. A study of the mechanism of the Jaffé reaction. Z Klin Chem Klin Biochem. 1974;12(7):336–343.
22.
LeveyASEckardtKUTsukamotoY. Definition and classification of chronic kidney disease: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int. 2005;67(6):2089–2100.
23.
National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis. 2002;39(2 suppl 1): S1–S266.
24.
O’HareAJohansenK. Lower-extremity peripheral arterial disease among patients with end-stage renal disease. J Am Soc Nephrol. 2001;12(12):2838–2847.
25.
RajagopalanSDellegrottaglieSFurnissAL. Peripheral arterial disease in patients with end-stage renal disease: observations from the Dialysis Outcomes and Practice Patterns Study (DOPPS). Circulation. 2006;114(18):1914–1922.
26.
LeveyASBoschJPLewisJBGreeneTRogersNRothD. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med. 1999;130(6):461–470.
27.
LeveyASStevensLASchmidCH. A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009(9);150(9):604–612.
28.
AthyrosVGMikhailidisDPPapageorgiouAA. The effect of statins versus untreated dyslipidaemia on renal function in patients with coronary heart disease. A subgroup analysis of the Greek atorvastatin and coronary heart disease evaluation (GREACE) study. J Clin Pathol. 2004;57(7):728–734.
29.
AlnaebMEYoussefFMikhailidisDP. Short-term lipid-lowering treatment with atorvastatin improves renal function but not renal blood flow indices in patients with peripheral arterial disease. Angiology. 2006;57(1):65–71.
30.
CampeseVMParkJ. HMG-CoA reductase inhibitors and renal function. Clin J Am Soc Nephrol. 2007;2(6):1100–1103.
31.
SandhuSWiebeNFriedLFTonelliM. Statins for improving renal outcomes: a meta-analysis. J Am Soc Nephrol. 2006;17(7):2006–2016.
32.
Heart Protection Study Collaborative Group. Randomized trial of the effects of cholesterol-lowering with simvastatin on peripheral vascular and other major vascular outcomes in 20,536 people with peripheral arterial disease and other high-risk conditions. J Vasc Surg. 2007;45(4):645–654.
33.
ColhounHMBetteridgeDJDurringtonPN. Effects of atorvastatin on kidney outcomes and cardiovascular disease in patients with diabetes: an analysis from the Collaborative Atorvastatin Diabetes Study (CARDS). Am J Kidney Dis. 2009;54(5):810–819.
34.
BarylskiMNikfarSMikhailidisDP. Statins decrease all-cause mortality only in CKD patients not requiring dialysis therapy--a meta-analysis of 11 randomized controlled trials involving 21,295 participants. Pharmacol Res. 2013;72:35–44.
35.
European Stroke Organisation, TenderaMAboyansVBartelinkML. ESC Guidelines on the diagnosis and treatment of peripheral artery diseases: document covering atherosclerotic disease of extracranial carotid and vertebral, mesenteric, renal, upper and lower extremity arteries: the Task Force on the Diagnosis and Treatment of Peripheral Artery Diseases of the European Society of Cardiology (ESC). Eur Heart J. 2011;32(22):2851–2906.
36.
YusufSSleightPPogueJBoschJDaviesRDagenaisG.Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med. 2000;342(3):145–153.
37.
MehtaRLKellumJAShahSV. Acute Kidney Injury Network: report of an initiative to improve outcomes in acute kidney injury. Crit Care. 2007;11(2): R31.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
